iohexol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1461	66108-95-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iohexol	An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Molecular weight: 821.14 Formula: C19H26I3N3O9 CLOGP: -2.44 LIPINSKI: 3 HAC: 12 HDO: 8 TPSA: 199.89 ALOGS: -3.01 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iohexol

An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Molecular weight: 821.14
Formula: C19H26I3N3O9
CLOGP: -2.44
LIPINSKI: 3
HAC: 12
HDO: 8
TPSA: 199.89
ALOGS: -3.01
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	95 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4597.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.80 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 1985	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	890.30	31.92	401	6187	165401	63317033
Sneezing	567.36	31.92	163	6425	18055	63464379
Pruritus	454.11	31.92	340	6248	361113	63121321
Contrast media reaction	442.99	31.92	80	6508	1045	63481389
Erythema	311.93	31.92	205	6383	175546	63306888
Extravasation	286.88	31.92	63	6525	2309	63480125
Throat irritation	232.13	31.92	101	6487	37546	63444888
Contrast media allergy	231.54	31.92	53	6535	2348	63480086
Throat tightness	177.27	31.92	74	6514	24813	63457621
Dyspnoea	140.44	31.92	247	6341	661066	62821368
Anaphylactic reaction	121.32	31.92	79	6509	66021	63416413
Anaphylactic shock	106.41	31.92	51	6537	23582	63458852
Chest discomfort	87.57	31.92	80	6508	109889	63372545
Chills	66.86	31.92	70	6518	113308	63369126
Eye swelling	65.54	31.92	37	6551	23881	63458553
Drug ineffective	62.45	31.92	16	6572	1044749	62437685
Pharyngeal oedema	59.89	31.92	29	6559	13692	63468742
Cough	57.29	31.92	106	6482	292637	63189797
Laryngeal oedema	54.52	31.92	21	6567	5697	63476737
Local anaesthetic systemic toxicity	51.29	31.92	13	6575	886	63481548
Hypersensitivity	51.12	31.92	101	6487	292584	63189850
Aneurysm ruptured	47.06	31.92	11	6577	533	63481901
Drug reaction with eosinophilia and systemic symptoms	46.78	31.92	34	6554	33802	63448632
Paraesthesia oral	45.34	31.92	27	6561	19229	63463205
Fatigue	45.17	31.92	18	6570	888010	62594424
Eye pruritus	43.50	31.92	26	6562	18645	63463789
Patent ductus arteriosus	41.92	31.92	16	6572	4234	63478200
Contrast encephalopathy	39.51	31.92	7	6581	81	63482353
Swelling face	38.83	31.92	40	6548	63435	63418999
Blood pressure decreased	38.02	31.92	40	6548	64982	63417452
Nasal congestion	37.70	31.92	40	6548	65620	63416814
Tongue pruritus	36.81	31.92	9	6579	529	63481905
Anaphylactoid reaction	36.66	31.92	14	6574	3709	63478725
Dysphagia	35.76	31.92	45	6543	88540	63393894
No adverse event	34.61	31.92	31	6557	41374	63441060
Papule	34.13	31.92	15	6573	5676	63476758
Sensation of foreign body	33.37	31.92	14	6574	4731	63477703
Swollen tongue	33.01	31.92	28	6560	34772	63447662
Tachypnoea	32.47	31.92	21	6567	17281	63465153
Tremor	32.46	31.92	53	6535	132186	63350248

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	584.83	28.14	245	4681	62132	34889873
Sneezing	402.43	28.14	102	4824	5140	34946865
Contrast media reaction	325.51	28.14	63	4863	883	34951122
Pruritus	260.66	28.14	190	4736	141791	34810214
Erythema	224.59	28.14	145	4781	88635	34863370
Contrast media allergy	196.86	28.14	37	4889	438	34951567
Extravasation	196.63	28.14	47	4879	1843	34950162
Anaphylactic reaction	160.24	28.14	82	4844	32219	34919786
Rash maculo-papular	106.67	28.14	60	4866	28391	34923614
Anaphylactic shock	95.33	28.14	46	4880	15895	34936110
Throat tightness	81.62	28.14	34	4892	8324	34943681
Chills	74.23	28.14	73	4853	80970	34871035
Throat irritation	67.70	28.14	32	4894	10553	34941452
Acute kidney injury	61.06	28.14	133	4793	304855	34647150
Overlap syndrome	47.75	28.14	9	4917	108	34951897
Anaphylactoid shock	47.41	28.14	11	4915	377	34951628
Hypersensitivity	45.03	28.14	49	4877	60986	34891019
Drug reaction with eosinophilia and systemic symptoms	44.48	28.14	37	4889	32975	34919030
Vomiting	43.86	28.14	103	4823	247518	34704487
Eye pruritus	39.93	28.14	20	4906	7469	34944536
Dyspnoea	35.66	28.14	125	4801	376657	34575348
Rash	34.43	28.14	88	4838	222664	34729341
Blood pressure decreased	33.93	28.14	39	4887	51476	34900529
Death	32.75	28.14	8	4918	398041	34553964
Eye swelling	31.88	28.14	19	4907	9976	34942029
Drug ineffective	30.84	28.14	13	4913	456738	34495267
Nephropathy toxic	30.26	28.14	20	4906	12568	34939437
Hypotension	28.65	28.14	82	4844	221567	34730438

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	1216.54	26.77	566	10635	184635	79548552
Sneezing	863.57	26.77	246	10955	19437	79713750
Contrast media reaction	688.93	26.77	134	11067	1936	79731251
Pruritus	641.84	26.77	490	10711	394158	79339029
Erythema	458.38	26.77	320	10881	222970	79510217
Extravasation	441.40	26.77	103	11098	3647	79729540
Contrast media allergy	359.66	26.77	81	11120	2441	79730746
Throat irritation	266.25	26.77	125	11076	40821	79692366
Anaphylactic reaction	247.04	26.77	151	11050	83592	79649595
Throat tightness	218.55	26.77	97	11104	27810	79705377
Anaphylactic shock	186.15	26.77	94	11107	35902	79697285
Dyspnoea	155.13	26.77	358	10843	856667	78876520
Chills	133.54	26.77	137	11064	160097	79573090
Rash maculo-papular	113.56	26.77	80	11121	55998	79677189
Eye swelling	97.02	26.77	55	11146	26413	79706774
Chest discomfort	92.09	26.77	105	11096	137939	79595248
Drug reaction with eosinophilia and systemic symptoms	84.66	26.77	71	11130	64173	79669014
Hypersensitivity	81.57	26.77	138	11063	262101	79471086
Eye pruritus	78.79	26.77	44	11157	20526	79712661
Drug ineffective	77.18	26.77	28	11173	1080885	78652302
Pharyngeal oedema	65.59	26.77	36	11165	16236	79716951
Acute kidney injury	65.44	26.77	190	11011	519214	79213973
Rash	64.82	26.77	203	10998	578155	79155032
Anaphylactoid shock	63.84	26.77	16	11185	765	79732422
Blood pressure decreased	63.50	26.77	74	11127	99392	79633795
Cough	62.26	26.77	150	11051	366639	79366548
Vomiting	60.71	26.77	218	10983	665610	79067577
Aneurysm ruptured	60.67	26.77	16	11185	938	79732249
Laryngeal oedema	56.43	26.77	26	11175	8103	79725084
Nephropathy toxic	55.47	26.77	35	11166	20384	79712803
Hypotension	52.46	26.77	158	11043	440159	79293028
No adverse event	50.83	26.77	42	11159	37150	79696037
Off label use	48.90	26.77	34	11167	907181	78826006
Angioedema	47.56	26.77	56	11145	75979	79657208
Papule	46.19	26.77	22	11179	7385	79725802
Nasal congestion	45.61	26.77	55	11146	76497	79656690
Swelling face	45.46	26.77	53	11148	71159	79662028
Lip swelling	45.37	26.77	41	11160	40870	79692317
Eyelid oedema	43.67	26.77	26	11175	13661	79719526
Tongue pruritus	43.24	26.77	11	11190	559	79732628
Tachypnoea	41.31	26.77	35	11166	32028	79701159
Rash erythematous	40.26	26.77	45	11156	57724	79675463
Fatigue	40.17	26.77	43	11158	929684	78803503
Infusion site extravasation	39.73	26.77	22	11179	10086	79723101
Anaphylactoid reaction	39.70	26.77	18	11183	5404	79727783
Paraesthesia oral	38.63	26.77	28	11173	20443	79712744
Contrast encephalopathy	37.74	26.77	8	11193	180	79733007
Diarrhoea	37.72	26.77	41	11160	880448	78852739
Death	36.51	26.77	17	11184	566497	79166690
Sensation of foreign body	36.27	26.77	17	11184	5505	79727682
Loss of consciousness	35.46	26.77	75	11126	167868	79565319
Lacrimation increased	34.13	26.77	27	11174	22450	79710737
Ocular hyperaemia	32.72	26.77	29	11172	28177	79705010
Injection site extravasation	32.50	26.77	19	11182	9650	79723537
Weight decreased	31.27	26.77	6	11195	355192	79377995
Swollen tongue	31.11	26.77	34	11167	42536	79690651
Tachycardia	30.39	26.77	73	11128	177695	79555492
Toxic skin eruption	30.09	26.77	25	11176	22268	79710919
Dysphagia	29.88	26.77	58	11143	122078	79611109
Cyanosis	29.42	26.77	26	11175	25156	79708031
Shock	28.77	26.77	33	11168	43515	79689672
Arthralgia	28.70	26.77	23	11178	571780	79161407
Overlap syndrome	28.37	26.77	9	11192	1015	79732172
Flushing	28.08	26.77	47	11154	88221	79644966
Fall	27.92	26.77	17	11184	487612	79245575
Cold sweat	27.40	26.77	22	11179	18677	79714510
Rash pustular	27.29	26.77	18	11183	11293	79721894

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB02	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA EPC	N0000180185	Radiographic Contrast Agent
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37338	contrast media
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.73	acidic
pKa2	11.33	acidic
pKa3	12.2	acidic
pKa4	13.65	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018251	VUID
N0000146581	NUI
D01817	KEGG_DRUG
4018251	VANDF
C0022005	UMLSCUI
CHEBI:31709	CHEBI
CHEMBL1200455	ChEMBL_ID
D007472	MESH_DESCRIPTOR_UI
DB01362	DRUGBANK_ID
4848	INN_ID
4419T9MX03	UNII
3730	PUBCHEM_CID
5956	RXNORM
4904	MMSL
d01456	MMSL
000673	NDDF
109218004	SNOMEDCT_US
395751002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	28 sections